Alexey Vinogradov
Director/Board Member at XENETIC BIOSCIENCES, INC.
Net worth: 70 532 $ as of 2024-04-29
Profile
Dr. Alexey A.
Vinogradov is an Independent Non-Executive Director at Xenetic Biosciences, Inc. and a Director-Operations & Business Development at Cantreva LLC.
He is on the Board of Directors at Pharmsynthez PJSC, Xenetic Biosciences, Inc. and Avelas Biosciences, Inc. Dr. Vinogradov was previously employed as a General Manager by Togas Middle East LLC, an Independent Director by Argos Therapeutics, Inc., a Branch Manager by Togas Group LLC, a Managing Partner by Pharmstandard Ventures, and an Investment Manager by Bioprocess Capital Partners Ltd.
He received his doctorate degree from Moscow State University Lomonosov.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2024-03-30 | 18,679 ( 1.21% ) | 70 532 $ | 2024-04-29 |
Alexey Vinogradov active positions
| Companies | Position | Start |
|---|---|---|
| XENETIC BIOSCIENCES, INC. | Director/Board Member | 2019-07-18 |
| PHARMSYNTHEZ | Director/Board Member | 2023-08-02 |
Avelas Biosciences, Inc.
 Avelas Biosciences, Inc. Medical/Nursing ServicesHealth Services Avelas Biosciences, Inc. develops integrated suite of therapeutic and imaging agents for treatment of cancer. It develops AVB-620, an intravenously administered in vivo fluorescent protease activatable peptide that detects, marks, and diagnoses cancer. The company was founded by Yon Chien Tsien, Quyen T. Nguyen and Michael A. Whitney in 2008 and is headquartered in La Jolla, CA. | Director/Board Member | 2017-03-13 |
| Cantreva LLC | Chief Operating Officer | 2017-08-31 |
Former positions of Alexey Vinogradov
| Companies | Position | End |
|---|---|---|
| Togas Middle East LLC | Corporate Officer/Principal | 2017-04-30 |
| Togas Group LLC | Corporate Officer/Principal | 2016-10-31 |
| ARGOS THERAPEUTICS, INC. | Director/Board Member | 2016-06-09 |
Bioprocess Capital Partners Ltd.
 Bioprocess Capital Partners Ltd. Investment ManagersFinance Bioprocess Capital Partners Ltd (BCP) is a venture capital firm founded in 2006. The firm is headquartered in Moscow, Russia. | Private Equity Investor | 2010-12-30 |
Pharmstandard Ventures
 Pharmstandard Ventures Investment ManagersFinance Pharmstandard Ventures (Pharmstd Ventures) is a venture capital subsidiary of Pharmstandard PJSC headquartered in Moscow, Russia. The firm was founded in 2013 by Dr. Andrey Petrov. | Chief Executive Officer | - |
Training of Alexey Vinogradov
| Moscow State University Lomonosov | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| XENETIC BIOSCIENCES, INC. | Health Technology |
| PHARMSYNTHEZ | Health Technology |
| Private companies | 7 |
|---|---|
Bioprocess Capital Partners Ltd.
Bioprocess Capital Partners Ltd. Investment ManagersFinance Bioprocess Capital Partners Ltd (BCP) is a venture capital firm founded in 2006. The firm is headquartered in Moscow, Russia. | Finance |
Pharmstandard Ventures
Pharmstandard Ventures Investment ManagersFinance Pharmstandard Ventures (Pharmstd Ventures) is a venture capital subsidiary of Pharmstandard PJSC headquartered in Moscow, Russia. The firm was founded in 2013 by Dr. Andrey Petrov. | Finance |
Argos Therapeutics, Inc.
 Argos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Argos Therapeutics, Inc. was a biopharmaceutical company. It engages in development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its proprietary technology platform called Arcelis. The firm's product include AGS-003 for the treatment of metastatic renal cell carcinoma, and other cancers; and AGS-004 for the treatment of human immunodeficiency virus. The company was founded by Bruce A. Sullenger, Eli Gilboa, John A. Irick and Ralph M. Steinman on May 8, 1997 and was headquartered in Durham, NC. | Health Technology |
Avelas Biosciences, Inc.
Avelas Biosciences, Inc. Medical/Nursing ServicesHealth Services Avelas Biosciences, Inc. develops integrated suite of therapeutic and imaging agents for treatment of cancer. It develops AVB-620, an intravenously administered in vivo fluorescent protease activatable peptide that detects, marks, and diagnoses cancer. The company was founded by Yon Chien Tsien, Quyen T. Nguyen and Michael A. Whitney in 2008 and is headquartered in La Jolla, CA. | Health Services |
| Cantreva LLC | |
| Togas Middle East LLC | |
| Togas Group LLC |
- Stock Market
- Insiders
- Alexey Vinogradov
